Compare AbCellera Biologics Inc (ABCL) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Lamb Weston Holdings Inc — how do they compare? AbCellera Biologics Inc trades at $9.97 (market cap $2.99B), while Lamb Weston Holdings Inc trades at $52.27 (market cap $7.23B). The key difference: Lamb Weston Holdings Inc is far larger — about 2.4× AbCellera Biologics Inc's market cap, and Lamb Weston Holdings Inc pays a 2.89% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | LW | |
|---|---|---|
Market Cap | $2.99B | $7.23B |
Sector | Health | Consumer Staples |
52-Week High | $9.76 | $66.57 |
52-Week Low | $2.78 | $38.48 |
Enterprise Value | $2.58B | $11.10B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
Lamb Weston (LW) trades at $51.81, down 0.88% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 16.28% ROE and a 4.39% net margin, supported by positive cash flow from operations of $868.3M in 2025. Recent news highlights Q4 2026 results exceeding expectations and a declared $0.38 dividend.
Outlook remains positive with a consensus price target of $53.86, though risks include margin pressure from cost inflation and international headwinds. The stock offers a solid dividend yield and growth potential from operational improvements, but investors should monitor debt levels and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
